Busca un médico

Hassan Alkhateeb, M.D.

  1. Hematologist
Solicite una Consulta

Publicaciones

  1. Katamesh B, Nanaa A, He R, Viswanatha D, Greipp PT, Bessonen K, Nguyen P, Jevremovic D, Yi CA, Foran J, Begna K, Gangat N, Mangaonkar A, Saliba AN, Patnaik MM, Hogan WJ, Litzow M, Tefferi A, Shah MV, Alkhateeb HB, Al-Kali A. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience. Ann Hematol 2024 Oct; 103 (10):4333-4336 Epub 2024 Aug 28
    View PubMed
  2. Palmisiano ND, Lee JW, Claxton DF, Paietta EM, Alkhateeb H, Park J, Podoltsev NA, Atallah EL, Schaar DG, Dinner SN, Webster JA, Luger SM, Litzow MR. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol. EJHaem. 2024 Oct; 5 (5):951-956 Epub 2024 Aug 08
    View PubMed
  3. Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 2024 Oct 1; 109 (10):3419-3425 Epub 2024 Oct 01
    View PubMed
  4. Baranwal A, Shah MV, Greipp P, Shi M, Reichard KK, Jevremovic D, Gangat N, Patnaik MM, Begna KH, Alkhateeb HB, Litzow MR, Hogan WJ, Tefferi A, Al-Kali A, Mangaonkar AA. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes. Br J Haematol 2024 Oct; 205 (4):1627-1631 Epub 2024 July 31
    View PubMed
  5. Mendoza MA, Bhaimia E, Alkhateeb HB, Razonable RR, Thoendel M. Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed-onset clinically significant cytomegalovirus infection after letermovir prophylaxis? Transpl Infect Dis. 2024 Sep 28; e14377 Epub 2024 Sept 28
    View PubMed
  6. Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Sep 26 Epub 2024 Sept 26
    View PubMed
  7. Tessier S, He R, Greipp P, Viswanatha D, Bessonen K, Lasho T, Foran J, Arana-Yi C, Gangat N, Tefferi A, Shah M, Alkhateeb H, Liu S, Pardanani A, Patnaik M, Al-Kali A. Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2024 Sep 24; 8 (18):4807-4811
    View PubMed
  8. Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, Greipp P, Bessonen K, Palmer J, Foran J, Saliba A, Hefazi-Torghabeh M, Begna K, Hogan W, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms. Leukemia. 2024 Sep 23 Epub 2024 Sept 23
    View PubMed
  9. Baranwal A, Langer KJ, Kharfan-Dabaja MA, Ayala E, Foran J, Murthy H, Roy V, Iqbal M, Palmer J, Sproat LZ, Chhabra S, Khera N, Durani U, Hefazi M, Mangaonkar A, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplant Cell Ther. 2024 Aug 16 [Epub ahead of print]
    View PubMed
  10. Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J 2024 Aug 12; 14 (1):136
    View PubMed
  11. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01
    View PubMed
  12. Li M, Baranwal A, Gurney M, Shah SN, Al-Kali A, Alkhateeb H, Foran J, Arana Yi C, Ongie L, Chen D, Mangaonkar A, McCullough K, Tefferi A, Lasho T, Finke C, Patnaik MM, Shah MV. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Adv. 2024 Jun 25; 8 (12):3130-3139
    View PubMed
  13. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience. Haematologica. 2024 Jun 20 Epub 2024 June 20
    View PubMed
  14. Vergidis P, Sendi P, Alkhateeb HB, Nguyen MH. How do I manage refractory invasive pulmonary aspergillosis. Clin Microbiol Infect. 2024 Jun; 30 (6):755-761 Epub 2024 Jan 28
    View PubMed
  15. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Jun 1; 109 (6):1779-1791 Epub 2024 June 01
    View PubMed
  16. Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04
    View PubMed
  17. Herasevich S, Schulte PJ, Hogan WJ, Alkhateeb H, Zhang Z, White BA, Khera N, Roy V, Gajic O, Yadav H. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study. Am J Respir Crit Care Med. 2024 Mar 1; 209 (5):543-552
    View PubMed
  18. Baranwal A, Basmaci R, He R, Viswanatha D, Greipp P, Murthy HS, Foran J, Palmer J, Hogan WJ, Litzow MR, Hefazi M, Mangaonkar A, Shah MV, Al-Kali A, Alkhateeb HB. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Adv. 2024 Feb 13; 8 (3):562-570
    View PubMed
  19. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  20. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
  21. Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Kelemen K, Orazi A, Chen D, Reichard KK. Mast cell cytomorphology and treatment outcome in mast cell leukemia. Am J Hematol 2024 Jan; 99 (1):E5-E8 Epub 2023 Sept 21
    View PubMed
  22. Nanaa A, He R, Foran JM, Badar T, Gangat N, Pardanani A, Hogan WJ, Litzow MR, Patnaik M, Al-Kali A, Alkhateeb HB. Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. Br J Haematol. 2024 Jan; 204 (1):171-176 Epub 2023 Sept 14
    View PubMed
  23. Gupta S, Kohorst M, Alkhateeb HB. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024 Jan; 112 (1):51-63
    View PubMed
  24. Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023 Nov 1; 108 (11):3170-3174 Epub 2023 Nov 01
    View PubMed
  25. Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023 Nov 1; 108 (11):3033-3043 Epub 2023 Nov 01
    View PubMed
  26. Yuan J, He R, Alkhateeb HB. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations. Curr Hematol Malig Rep. 2023 Oct; 18 (5):121-129 Epub 2023 June 01
    View PubMed
  27. Badar T, Vanegas YAM, Nanaa A, Foran JM, Al-Kali A, Mangaonkar A, Murthy H, Alkhateeb HB, Viswanatha D, He R, Shah M, Yi CA, Litzow MR, Gangat N, Tefferi A, Patnaik MM. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023 Sep 21; 13 (1):149 Epub 2023 Sept 21
    View PubMed
  28. Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematologica 2023 Sep 1; 108 (9):2542-2545 Epub 2023 Sept 01
    View PubMed
  29. Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer J. 2023 Aug 11; 13 (1):122
    View PubMed
  30. Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia 2023 Aug; 37 (8):1753-1756 Epub 2023 July 08
    View PubMed
  31. Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023 Jul 18; 13 (1):108 Epub 2023 July 18
    View PubMed
  32. Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023 Jul; 202 (2):279-283 Epub 2023 May 05
    View PubMed
  33. Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb HB, Singhal D, Cibich A, Bardy P, Kok CH, Hiwase DK, Shah MV. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023 Jul; 58 (7):769-776 Epub 2023 Apr 03
    View PubMed
  34. Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood Adv. 2023 Jun 27; 7 (12):2694-2698
    View PubMed
  35. Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 Jun; 29 (6):360.e1-360.e8 Epub 2023 Feb 09
    View PubMed
  36. Matin A, Smith BH, Mangaonkar A, Duffy DJ, Wolf R, Alkhateeb H, Shah MV, Hogan WJ, Litzow MR. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 May; 29 (5):324.e1-324.e6 Epub 2023 Jan 20
    View PubMed
  37. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2023 Apr 25; 7 (8):1351-1355
    View PubMed
  38. Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. TP53 mutation variant allele frequency of >/=10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J. 2023 Apr 11; 13 (1):51
    View PubMed
  39. Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J 2023 Apr 10; 13 (1):49
    View PubMed
  40. Badar T, Alkhateeb H, Aljurf M, Kharfan-Dabaja MA. Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era. Curr Res Transl Med. 2023 Apr-Jun; 71 (2):103392 Epub 2023 Apr 23
    View PubMed
  41. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023 Mar 2; 141 (9):1087-1091
    View PubMed
  42. Singhal S, Saadeh SS, Durani U, Kansagra A, Alkhateeb HB, Shah MV, Mangaonkar A, Kenderian S, Hashmi S, Patnaik MV, Litzow MR, Hogan WJ. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience. Transplant Cell Ther. 2023 Mar; 29 (3):183.e1-183.e6 Epub 2022 Dec 28
    View PubMed
  43. Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, Litzow M. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. Am J Hematol. 2023 Mar; 98 (3):472-480 Epub 2023 Jan 22
    View PubMed
  44. Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, Khurana A, Wang Y, Paludo J, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, Lin Y, Alkhateeb HB. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood Cancer J 2023 Jan 5; 13 (1):7 Epub 2023 Jan 05
    View PubMed
  45. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. Haematologica 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01
    View PubMed
  46. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. Ann Hematol 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04
    View PubMed
  47. Herasevich S, Frank RD, Hogan WJ, Alkhateeb H, Limper AH, Gajic O, Yadav H. Post-Transplant and In-Hospital Risk Factors for ARDS After Hematopoietic Stem Cell Transplantation. Respir Care. 2023 Jan; 68 (1):77-86 Epub 2022 Sept 20
    View PubMed
  48. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03
    View PubMed
  49. Baranwal A, Nanaa A, Viswanatha D, He R, Foran J, Badar T, Hogan WJ, Litzow MR, Shah MV, Patnaik MM, Al-Kali A, Alkhateeb HB. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. Bone Marrow Transplant 2022 Nov; 57 (11):1716-1718 Epub 2022 Aug 20
    View PubMed
  50. Jevremovic D, Nanaa A, Geyer SM, Timm M, Azouz H, Hengel C, Reberg A, He R, Viswanatha D, Salama ME, Shi M, Olteanu H, Horna P, Otteson G, Greipp PT, Xie Z, Alkhateeb HB, Hogan W, Litzow M, Patnaik MM, Shah M, Al-Kali A, Nguyen PL. Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance. Am J Clin Pathol. 2022 Oct 6; 158 (4):530-536
    View PubMed
  51. Singh A, Alkhateeb H, Pardanani A, He R, Orazi A, Tefferi A, Reichard KK. Mast cell sarcoma: 2 Mayo Clinic cases. Am J Hematol. 2022 Oct; 97 (10):1381-1383 Epub 2022 Mar 21
    View PubMed
  52. Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01
    View PubMed
  53. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01
    View PubMed
  54. Marshall AL, Halfdanarson TR, Alkhateeb H, Hobday T. Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources. J Cancer Educ. 2022 Oct; 37 (5):1385-1388 Epub 2021 Jan 30
    View PubMed
  55. Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Comparison between GATA2 and DDX41-mutated myeloid neoplasms. Leuk Res 2022 Oct; 121:106931 Epub 2022 Aug 23
    View PubMed
  56. Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022 Sep 13; 6 (17):5227-5231
    View PubMed
  57. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30
    View PubMed
  58. Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. Am J Hematol. 2022 Aug; 97 (8):1013-1022 Epub 2022 May 27
    View PubMed
  59. Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, Murthy H, Kharfan-Dabaja M, Bisneto Villasboas JC, Bennani N, Ansell SM, Patnaik MM, Litzow MR, He R, Chen D, Al-Kali A, Kenderian SS, Lin Y, Shah MV. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. Blood Cancer J 2022 Jul 26; 12 (7):113 Epub 2022 July 26
    View PubMed
  60. Kutzke JL, Merten JA, Pawlenty AG, Barreto EF, Bartoo GT, Mara KC, Litzow MR, Hogan WJ, Shah MV, Mangaonkar AA, Leung N, Alkhateeb HB. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Adv. 2022 Jul 12; 6 (13):3844-3849
    View PubMed
  61. Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J. 2022 Jul 8; 12 (7):106 Epub 2022 July 08
    View PubMed
  62. Nasr SH, Leung N, Said SM, Alkhateeb HB, Madden BJ, Charlesworth MC, Beck LH Jr, Larsen CP, Sethi S. Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases. Am J Kidney Dis. 2022 Jun; 79 (6):904-908 Epub 2021 Sept 08
    View PubMed
  63. Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01
    View PubMed
  64. Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2022 May; 57 (5):852
    View PubMed
  65. Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj-Spinner AP, Mangaonkar A, He R, Pardanani A, Shah M, Ketterling RP, Tefferi A. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3". Blood Cancer J 2022 Apr 7; 12 (4):55 Epub 2022 Apr 07
    View PubMed
  66. Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Orti G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022 Apr; 28 (4):187.e1-187.e10 Epub 2022 Jan 23
    View PubMed
  67. May HP, Bartoo GT, Wolf RC, Shah MV, Litzow MR, Hogan WJ, Alkhateeb H. Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. J Oncol Pharm Pract. 2022 Mar; 28 (2):387-394 Epub 2021 Feb 16
    View PubMed
  68. Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, Litzow MR, Ketterling RP, Greipp PT, Foran JM. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 Feb; 196 (4):963-968 Epub 2021 Oct 25
    View PubMed
  69. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J 2022 Jan 25; 12 (1):12
    View PubMed
  70. Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022 Jan 25; 6 (2):528-532
    View PubMed
  71. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J. 2022 Jan 25; 12(1):12.
    View PubMed
  72. Begna KH, Kittur J, Gangat N, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer J. 2022 Jan 17; 12 (1):7
    View PubMed
  73. Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood 2021 Dec 30; 138 (26):2886-2889
    View PubMed
  74. Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 Dec; 56 (12):3068-3077 Epub 2021 Sept 28
    View PubMed
  75. Nadiminti K, Langer K, Shabbir E, Hefazi M, Dozeman L, Jethava Y, Loeffler B, AlKhateeb HB, Litzow M, Patnaik M, Shah M, Hogan W, Farooq U, Silverman M, Mott SL. A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer J. 2021 Nov 20; 11 (11):183
    View PubMed
  76. Kompotiatis P, Manohar S, Alkhateeb HB, Hogan WJ, Nath KA, Leung N. Hemoglobinuria in the Early Poststem-Cell-Transplant Period: Risk Factors and Association with Outcomes. Kidney360. 2021 Oct 28; 2 (10):1569-1575 Epub 2021 Aug 25
    View PubMed
  77. Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, Litzow MR, Baughn LB, Patnaik M, Greipp PT, Foran JM. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer J 2021 Sep 21; 11 (9):156 Epub 2021 Sept 21
    View PubMed
  78. Johnson I, Alkhateeb H. Osteolytic lesions in myelofibrosis. Clin Case Rep. 2021 Jul; 9 (7):e04276 Epub 2021 July 19
    View PubMed
  79. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021 Jul 1; 96 (7):781-789 Epub 2021 May 06
    View PubMed
  80. Nanaa A, Viswanatha D, Xie Z, Jevremovic D, Nguyen P, Salama ME, Greipp P, Bessonen K, Gangat N, Patnaik M, Pardanani A, Alkhateeb HB, Shah M, Hogan W, Tefferi A, Litzow M, He R, Al-Kali A. Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer J 2021 Jun 30; 11 (6):122 Epub 2021 June 30
    View PubMed
  81. Herasevich S, Frank RD, Bo H, Alkhateeb H, Hogan WJ, Gajic O, Yadav H. Pretransplant Risk Factors Can Predict Development of Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell Transplantation. Ann Am Thorac Soc. 2021 Jun; 18 (6):1004-1012
    View PubMed
  82. Saw JL, Sidiqi MH, Mauermann ML, Alkhateeb H, Naddaf E. Immune-mediated neuromuscular complications of graft-versus-host disease. Muscle Nerve. 2021 Jun; 63 (6):852-860 Epub 2021 Mar 12
    View PubMed
  83. Wieruszewski PM, May HP, Peters SG, Gajic O, Hogan WJ, Dierkhising RA, Alkhateeb HB, Yadav H. Characteristics and Outcome of Periengraftment Respiratory Distress Syndrome after Autologous Hematopoietic Cell Transplant. Ann Am Thorac Soc. 2021 Jun; 18 (6):1013-1019
    View PubMed
  84. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021 Apr 27; 5 (8):2272-2278
    View PubMed
  85. Kutzke JL, Merten JA, Taraba JL, Mara KC, Shah MV, Hashmi SK, Patnaik MM, Litzow MR, Hogan WJ, Alkhateeb HB. Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplant. 2021 Apr; 56 (4):960-962 Epub 2020 Oct 31
    View PubMed
  86. Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, Patnaik M, Kumar S, Gertz M, Chen D, Shah MV. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2021 Mar 19; 11 (3):63
    View PubMed
  87. Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, Litzow MR, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04
    View PubMed
  88. Meleveedu KS, Chen D, Nadiminti K, Sidiqi H, Khan S, Alkhateeb H, Shah MV, Patnaik M, Hogan WJ, Begna K, Litzow M. PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leuk Lymphoma 2021 Mar; 62 (3):764-767 Epub 2019 Oct 12
    View PubMed
  89. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, Litzow M, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer J 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01
    View PubMed
  90. Abdel Rahman ZH, Heckman MG, Miller K, Alkhateeb H, Patnaik MS, Sproat LZ, Jiang L, Roy V, Murthy HS, Ayala E, Hogan WJ, Greipp PT, Kharfan-Dabaja MA, Litzow MR, Foran JM. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplant Cell Ther. 2021 Feb; 27 (2):165.e1-165.e11 Epub 2020 Dec 11
    View PubMed
  91. Singh P, Razonable RR, Lorenz EC, DiCaudo DJ, Sukov WR, Bridges AG, Alkhateeb HB, Hogan WJ, Klomjit N, Thirunavukkarasu S, Amer H, Kudva YC, Khamash H, Stegall M, Kukla A. Chronic graft-versus-host disease in pancreas after kidney transplant recipients - An unrecognized entity. Am J Transplant. 2021 Feb; 21 (2):883-888 Epub 2020 Sept 20
    View PubMed
  92. Madhavan AA, Carr CM, Alkhateeb H, Staff NP, Naddaf E. Nelarabine-Induced Myelotoxicity. Neurology. 2021 Jan 26; 96 (4):175-176 Epub 2020 Dec 11
    View PubMed
  93. Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR. The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. Blood Lymphat Cancer. 2021; 11:1-9 Epub 2021 Jan 22
    View PubMed
  94. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020 Dec; 95 (12):1511-1521 Epub 2020 Sept 16
    View PubMed
  95. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020 Nov 10; 4(21):5425-5430.
    View PubMed
  96. Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, Kumar SK, Litzow MR, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020 Oct; 95 (10):1170-1179 Epub 2020 Aug 08
    View PubMed
  97. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcarcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul 14; 4 (13):3180-3190
    View PubMed
  98. Joshi M, Greipp P, Ball C, Vinod Shah M, Khurana A, Yogarajah M, Nguyen P, He R, Viswanatha D, Jevremovic D, Salama M, Alkhateeb HB, Gangat N, Patnaik M, Begna K, Hogan W, Zblewski D, Litzow M, Al-Kali A. Characteristics of patients with myelodysplastic syndrome with balanced translocations. Br J Haematol. 2020 Jul; 190 (2):244-248 Epub 2020 Mar 17
    View PubMed
  99. Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, Patnaik MS, Pruthi RK, Marshall AL, Litzow MR, Elliott MA, Hogan WJ, Shah MV, Begna KH, Alkhateeb H, Pardanani A, Ashrani AA, Call TG, Rivera CE, Camoriano JK, Go RS, Wolanskyj-Spinner AP, Parikh SA. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020 Jul; 61 (7):1592-1600 Epub 2020 Mar 11
    View PubMed
  100. Alkhateeb HB, Patnaik MM, Al-Kali A, Zblewski DL, Wallerich S, McTavish H, Dudek AZ. Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. Anticancer Res. 2020 Jul; 40 (7):3883-3888
    View PubMed
  101. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR, Al-Kali A. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Ann Hematol. 2020 Mar; 99 (3):513-518 Epub 2020 Jan 23
    View PubMed
  102. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33 (3):334-343 Epub 2019 Aug 30
    View PubMed
  103. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33(3):514.
    View PubMed
  104. Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM. Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. Am J Hematol 2020 Mar; 95 (3):E68-E72 Epub 2020 Jan 26
    View PubMed
  105. Hasan Albitar HA, Egan AM, Alkhateeb H, Almodallal Y, Iyer VN. Marked hypereosinophilia secondary to endometrioid ovarian cancer presenting with asthma symptoms, a case report. Respir Med Case Rep. 2020; 31:101178 Epub 2020 July 28
    View PubMed
  106. Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, Litzow MR, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019 Jun; 25 (6):1232-1239 Epub 2019 Feb 15
    View PubMed
  107. Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovo A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdes-Sanz N. Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 May; 54 (5):782-783
    View PubMed
  108. Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovo A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdes-Sanz N. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 May; 54 (5):648-661 Epub 2019 Feb 27
    View PubMed
  109. Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovo A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hashmi S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdes-Sanz N. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 May; 25 (5):e145-e154 Epub 2018 Dec 03
    View PubMed
  110. Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leuk Lymphoma. 2019 Apr; 60 (4):990-999 Epub 2018 Oct 02
    View PubMed
  111. Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Ann Hematol. 2019 Feb; 98 (2):331-337 Epub 2018 Oct 18
    View PubMed
  112. Alkharabsheh O, Saadeh SS, Patnaik MS, Alkhateeb H, Gangat N, Begna KH, Hogan WJ, Greipp PT, He R, Nguyen PL, Litzow MR, Al-Kali A. Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. Am J Hematol 2018 Dec; 93 (12):E398-E401 Epub 2018 Oct 09
    View PubMed
  113. Vera-Aguilera J, Duma N, Gast K, Alkhateeb H, Tande A, Leung N, Hogan WJ, Kenderian SJ. Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient. Mayo Clin Proc Innov Qual Outcomes. 2018 Dec; 2 (4):387-391 Epub 2018 Sept 15
    View PubMed
  114. Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. Am J Hematol 2018 Nov; 93 (11):E355-E357 Epub 2018 Oct 02
    View PubMed
  115. Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, Murad MH, Al-Kali A. A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. Syst Rev. 2018 Sep 19; 7 (1):144 Epub 2018 Sept 19
    View PubMed
  116. Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep; 21 (3):431-437 Epub 2018 June 01
    View PubMed
  117. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR. Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome by the Revised International Prognostic Scoring System Blood. 2018; 132:5510.
  118. Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, Alkhateeb H, Kansagra A, Damlaj M, Patnaik MM. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Sep; 23 (9):1478-1484 Epub 2017 May 08
    View PubMed
  119. Schaefer JK, Alkhateeb HB, Thompson CA. 66-Year-Old Woman With Falls and Confusion. Mayo Clin Proc. 2017 Feb; 92 (2):e15-e19
    View PubMed
  120. Mangaonkar A, Khateeb HA, Duma N, St Louis EK, McKeon A, Patnaik M, Hogan W, Litzow M, Kourelis T. Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Case Rep Hematol. 2017; 2017:6803804 Epub 2017 Aug 27
    View PubMed
  121. Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, Gastineau DA, Al-Kali A, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016 Dec; 18 (6):913-920 Epub 2016 Nov 11
    View PubMed
  122. Binder M, Alkhateeb HB, Go RS. 61-Year-Old Man With Right Knee Pain and Chronic Anemia. Mayo Clin Proc. 2016 Nov; 91 (11):1640-1644 Epub 2016 Aug 04
    View PubMed
  123. Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Hashmi S, Gastineau DA, Al-Kali A, Wolf RC, Gangat N, Litzow MR, Hogan WJ, Patnaik MM. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biol Blood Marrow Transplant. 2016 Aug; 22 (8):1431-1439 Epub 2016 May 07
    View PubMed
  124. Damlaj M, Bartoo G, Cartin-Ceba R, Gijima D, Alkhateeb HB, Merten J, Hashmi S, Litzow M, Gastineau D, Hogan W, Patnaik MM. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016 Apr; 18: (2)216-26.
    View PubMed
  125. Hefazi M, Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015 Sep 3 Epub 2015 Sept 03
    View PubMed
  126. Alsahlawi A, Alkhateeb H, Patnaik M, Begna K, Elliott M, Hogan WJ, Litzow M, Al-Kali A. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):e39-41. Epub 2014 Jun 10.
    View PubMed
  127. Almerie MQ, Matar HE, Essali A, Alkhateeb H, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Schizophr Bull. 2008 Jan; 34 (1):13-4 Epub 2007 Nov 05
    View PubMed
PST-20435774